CLAIMS:

1. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a fixed-dose pharmaceutical composition for treating symptoms associated with allergic rhinitis in a pediatric human subject in need thereof, wherein (i) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily, ~~and~~ (ii) each spray comprises about 25 mcg of mometasone furoate and about 665 mcg olopatadine hydrochloride, and (iii) the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form.

2. The use of claim 1, wherein the symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.

3. The use of claim 1 or claim 2, wherein the pediatric human subject is 2 to 11 years of age.

4. The use of claim 1, wherein the allergic rhinitis is seasonal allergic rhinitis.

5. The use of claim 1, wherein the allergic rhinitis is perennial allergic rhinitis.

6. The use of any one of claims 1-5, wherein administration of the pharmaceutical composition provides relief from one or more symptoms of allergic rhinitis within 15 minutes of administration.

7. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a fixed dose pharmaceutical composition for treating allergic rhinitis in a pediatric human subject in need thereof, wherein (i) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily, (ii) each spray comprises about 25 mcg of mometasone furoate and about 665 mcg olopatadine hydrochloride, (iii) the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form and (~~iii~~iv) the administration provides relief from one or more symptoms of allergic rhinitis faster than nasal administration of 25 mcg mometasone furoate or 665 mcg olopatadine hydrochloride alone.

8. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a pharmaceutical composition for treating allergic rhinitis in a pediatric human subject, wherein

(a) the composition is prescribed to a pediatric human subject for twice daily nasal administration of one spray per nostril, wherein (i) the pharmaceutical composition comprises mometasone furoate and olopatadine hydrochloride, ~~and~~ (ii) each spray of the pharmaceutical composition comprises about 25 mcg of mometasone furoate and about 665 mcg of olopatadine hydrochloride, and (iii) the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form, and (ii) the prescribing is performed in response to (A) marketing of the pharmaceutical composition as providing (I) faster onset of action for relief of one or more symptoms of allergic rhinitis than nasal administration of mometasone furoate or olopatadine hydrochloride alone or (II) onset of action for relief of one or more symptoms of allergic rhinitis within 15 minutes of administration, and (B) diagnosis of the subject as suffering from allergic rhinitis; and

(b) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily.

9. The use of claim 8, wherein the symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.

10. The use of claim 8 or claim 9, wherein the pediatric human subject is 2 to 11 years of age.

11. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a pharmaceutical composition for treating allergic rhinitis in a pediatric human subject, wherein

(i) the composition is nasally administered as one spray per nostril of the pediatric human subject twice daily,

(ii) the pharmaceutical composition comprises mometasone furoate and olopatadine hydrochloride, ~~and~~ each spray of the pharmaceutical composition comprises about 25 mcg of mometasone furoate and about 665 mcg of olopatadine hydrochloride, and the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form, and

(iii) the pharmaceutical composition is to be administered to the pediatric human subject after being prescribed in response to (a) marketing of the pharmaceutical composition as providing (I) faster onset of action for relief of symptoms of allergic rhinitis than nasal

administration of mometasone ~~or its salt~~furoate or olopatadine ~~or its salt alone~~hydrochloride or (II) onset of action for relief of one or more symptoms of allergic rhinitis within 15 minutes of administration, and (b) a diagnosis of the pediatric human subject as suffering from allergic rhinitis.

12. The use of claim 11, wherein the symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.

13. The use of claim 11 or claim 12, wherein the pediatric human subject is 2 to 11 years of age.

14. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a pharmaceutical composition for treating allergic rhinitis in a pediatric human subject in need thereof, wherein (i) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily, (ii) the pharmaceutical composition provides an onset of action within 15 minutes for the treatment of allergic rhinitis, ~~and~~ (iii) each spray of the pharmaceutical composition comprises about 25 mcg of mometasone furoate and about 665 mcg of olopatadine hydrochloride, and (iv) the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form.

15. The use of claim 14, wherein the pediatric human subject is 2 to 11 years of age.

16. A fixed-dose pharmaceutical composition comprising mometasone furoate and olopatadine hydrochloride for use in a method of treating symptoms associated with allergic rhinitis in a pediatric human subject in need thereof, wherein (i) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily, ~~and~~ (ii) each spray comprises about 25 mcg of mometasone furoate and about 665 mcg olopatadine hydrochloride, and (iii) the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form.